Chronometric analysis of heparins on optical and mechanical coagulometers using the prothrombinase induced clotting test (PiCT®).

被引：0
|
作者：
Gempeler-Messina, MP
Bühler, B
Pötzsch, B
Calatzis, A
机构：
[1] Pentapharm Ltd, CH-4002 Basel, Switzerland
[2] Univ Bonn, D-5300 Bonn, Germany
[3] Univ Munich, Munich, Germany
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4092
引用
收藏
页码：94B / 95B
页数：2
相关论文
共 50 条
  • [1] Monitoring recombinant hirudin therapy using the Ecarin Clotting Time;: Heptest® and the prothrombinase induced clotting test (PiCT®).
    Calatzis, A
    Haas, S
    Wilmer, M
    Bühler, B
    Spannagl, M
    BLOOD, 2000, 96 (11) : 91B - 91B
  • [2] A new strategy for the monitoring of UFH, LMWH and hirudin:: The prothrombinase induced clotting test (PiCT®).
    Calatzis, A
    Gempeler-Messina, MP
    Kolde, HJ
    Haas, S
    BLOOD, 2000, 96 (11) : 91B - 91B
  • [3] The prothrombinase induced clotting time test (PICT®), a robust alternative to aptt in the management of ufh therapy
    Korte, W.
    Marlar, R.
    Krause, M.
    Rathbun, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 : 18 - 19
  • [4] Monitoring of parenteral anticoagulant drugs with the prothrombinase induced clotting time (PICT)
    Hoppensteadt, D.
    Walenga, J. M.
    Cunanan, J.
    Iqbal, O.
    Fareed, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 569 - 569
  • [5] Prothrombinase induced clotting time (PICT) for the monitoring of new oral anticoagulants
    Hoppensteadt, D.
    Walenga, J. M.
    Cunanan, J.
    Iqbal, O.
    Fareed, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 824 - 825
  • [6] Monitoring of unfractionated heparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent (PiCT®)
    Schaden, E.
    Jilch, S.
    Hacker, S.
    Schober, A.
    Kozek-Langenecker, S.
    CLINICA CHIMICA ACTA, 2012, 414 : 202 - 205
  • [7] Prothrombinase induced clotting time (PiCT®) for measuring the activity of direct factor Xa inhibitors in clinical setting
    Olivera, P. E.
    Cortina, V
    Pons, V
    Merchan, B.
    Lopez-Andreoni, L.
    Artaza, G.
    Menino, E.
    Marin, A.
    Bosch, F.
    Santamaria, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 643 - 643
  • [8] DETERMINATION OF THE ANTICOAGULANT EFFECT OF ENOXAPARIN IN VITRO WITH ROTATIONAL THROMBELASTOMETRY (ROTEM®) USING THE PROTHROMBINASE-INDUCED CLOTTING TIME REAGENT (PICT®)
    Schaden, E.
    Schober, A.
    Hacker, S.
    Spiss, C.
    Chiari, A.
    Kozek-Langenecker, S.
    INTENSIVE CARE MEDICINE, 2009, 35 : 277 - 277
  • [9] Preincubation in the Prothrombinase-induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban
    Kluft, C.
    Meijer, P.
    Kret, R.
    Burggraaf, J.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2013, 35 (04) : 379 - 384
  • [10] Comparative study on the anticoagulant effects of low molecular weight heparins as measured by whole blood ACT, anti-Xa and a newly developed prothrombinase induced clotting time (PiCT) assay
    Hoppensteadt, D
    Tobu, M
    Wahi, R
    Iqbal, O
    Walenga, JM
    Demir, M
    Baltasar, F
    Fareed, J
    BLOOD, 2005, 106 (11) : 117B - 117B
12345